Bulk Pharmaceutical API Sources for bortezomib

Bulk Pharmaceutical API Sources for bortezomib

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		387447
ISpharm		I14-3268
MolPort		MolPort-003-845-298
Alsachim		1188
ABI Chem		AC1L8TUW

Borteomizib Bulk Active Pharmaceutical Ingredient (API) Sourcing Landscape

Last updated: February 19, 2026

Bortezomib, a proteasome inhibitor, is a critical component in the treatment of multiple myeloma and mantle cell lymphoma. Sourcing bulk Active Pharmaceutical Ingredient (API) for bortezomib involves identifying manufacturers capable of producing this complex peptide-based molecule under stringent Good Manufacturing Practice (GMP) standards. The supply chain for bortezomib API is characterized by a limited number of specialized manufacturers and evolving patent landscapes that influence market entry and competition.

What is Bortezomib and Its Therapeutic Application?

Bortezomib is a reversible proteasome inhibitor. The proteasome is a protein complex within cells that breaks down unneeded or damaged proteins. In cancer cells, particularly in multiple myeloma, the proteasome plays a role in regulating cell growth and survival. By inhibiting the proteasome, bortezomib disrupts these processes, leading to apoptosis (programmed cell death) of cancer cells.

Bortezomib is approved for:

• Multiple Myeloma: In combination with melphalan and prednisone for newly diagnosed patients who are not eligible for autologous stem cell transplant. It is also used as a single agent or in combination with other drugs for patients with multiple myeloma who have received at least one prior therapy and whose disease has progressed.
• Mantle Cell Lymphoma: As a single agent for patients with mantle cell lymphoma whose disease has progressed after at least one prior therapy.

The complexity of bortezomib’s molecular structure, a dipeptidyl boronic acid, necessitates advanced synthetic capabilities and rigorous quality control in its manufacturing.

Who Manufactures Bortezomib API?

The manufacturing of bortezomib API is concentrated among a few key players, often operating under contract manufacturing agreements or as authorized suppliers. The proprietary nature of the manufacturing process and patent protections historically limited the number of sources. However, as patents approach expiry or have expired in certain regions, the market has seen potential for increased generic API production.

Key entities involved in or capable of manufacturing bortezomib API include:

• Original Innovator/Brand Manufacturer: Takeda Pharmaceutical Company, through its acquisition of Millennium Pharmaceuticals, is the originator of bortezomib (marketed as Velcade). They likely maintain in-house manufacturing or have established long-term contracts with highly specialized CMOs.
• Contract Manufacturing Organizations (CMOs): Several global CMOs possess the expertise and infrastructure for complex peptide synthesis and boronic acid chemistry. These companies often supply API to generic drug manufacturers. Identifying specific CMOs publicly associated with bortezomib API production can be challenging due to confidentiality agreements. However, companies with strong capabilities in peptide synthesis and heterocyclic chemistry are prime candidates.
• Generic API Manufacturers: Companies specializing in the production of generic APIs, particularly those with experience in oncology drugs and complex molecules, are increasingly entering the bortezomib API market, especially in regions where patents have lapsed. These manufacturers often aim to supply finished dosage form manufacturers.

Detailed, public lists of all bortezomib API manufacturers are not readily available due to commercial sensitivities and the dynamic nature of the supply chain. However, regulatory filings (e.g., Drug Master Files with the FDA or equivalent bodies) and patent litigation databases offer insights into potential and active suppliers.

What are the Regulatory and Quality Requirements for Bortezomib API?

The production of bortezomib API must adhere to strict global regulatory standards to ensure patient safety and drug efficacy. The primary requirement is compliance with current Good Manufacturing Practices (cGMP).

Key regulatory and quality aspects include:

• cGMP Compliance: Facilities manufacturing bortezomib API must be inspected and approved by regulatory authorities such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and national regulatory bodies in other key markets. This includes rigorous control over raw materials, manufacturing processes, facility operations, equipment, quality control, and documentation.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. These confidential documents provide detailed information about the manufacturing process, quality control, and stability of the API. Finished drug product manufacturers reference these DMFs in their marketing authorization applications.
• Impurity Profiling and Control: Given the complexity of bortezomib synthesis, thorough impurity profiling is critical. Manufacturers must identify, quantify, and control all process-related impurities and degradation products to meet pharmacopoeial standards (e.g., USP, EP) and regulatory guidelines (e.g., ICH Q3A/B).
• Stability Studies: Comprehensive stability data are required to demonstrate that the API remains within its defined specifications throughout its proposed shelf life under various storage conditions. This involves studies according to ICH Q1A(R2) guidelines.
• Supply Chain Security and Traceability: Robust systems are needed to ensure the integrity and traceability of the API from its point of manufacture to its use in finished drug products, mitigating risks of counterfeiting or adulteration.
• Pharmacopoeial Standards: The API must meet the specifications outlined in relevant pharmacopoeias, such as the United States Pharmacopeia (USP) or the European Pharmacopoeia (EP), if monographed.

The synthesis of bortezomib involves chiral centers and boronic acid functionalities, which present unique challenges in achieving high purity and consistent quality.

What is the Patent Landscape for Bortezomib?

The patent landscape significantly influences the accessibility and cost of bortezomib API. The original patents covering the compound, its synthesis, and its use are expiring or have expired in various jurisdictions, opening doors for generic competition.

Key patent considerations:

• Composition of Matter Patents: These are fundamental patents protecting the bortezomib molecule itself. These are typically the longest-lasting patents.
• Process Patents: Patents may cover specific synthetic routes or methods of manufacturing bortezomib. Generic manufacturers may develop alternative, non-infringing synthetic processes.
• Formulation Patents: Patents may cover specific formulations of bortezomib, such as lyophilized powders for injection.
• Method of Use Patents: Patents can protect specific therapeutic applications or dosage regimens.

Timeline and Expiry:

• The original U.S. patent for bortezomib (e.g., U.S. Patent No. 6,627,629) has expired.
• Key European patents have also expired, leading to the introduction of generic bortezomib in European markets. For instance, the Supplementary Protection Certificates (SPCs) in Europe covering the core compound have expired.
• The patent expiry dates vary by country and by specific patent covering different aspects of the drug.

Impact of Patent Expiry on API Sourcing:

• Increased Competition: Patent expiry allows generic API manufacturers to enter the market, leading to increased supply and potentially lower prices.
• Freedom to Operate (FTO): Generic API manufacturers must conduct thorough FTO analyses to ensure their manufacturing processes and products do not infringe on any remaining active patents.
• ANDA Filings: Generic drug manufacturers file Abbreviated New Drug Applications (ANDAs) with the FDA, referencing the approved brand-name drug and demonstrating bioequivalence. Successful ANDA approvals are contingent on the API meeting all quality standards and not infringing on patents.

Monitoring patent databases (e.g., USPTO, EPO, WIPO) and litigation dockets is crucial for understanding the current and future availability of non-infringing bortezomib API.

What are the Challenges and Opportunities in Bortezomib API Sourcing?

Sourcing bortezomib API presents both significant challenges and emerging opportunities for pharmaceutical companies.

Challenges:

• Complex Synthesis: Bortezomib is a complex molecule requiring specialized expertise in peptide chemistry and handling of boronic acids, which can be sensitive and require specific reaction conditions and purification techniques.
• High Purity Requirements: Achieving and consistently maintaining the high purity and quality required for an injectable oncology drug is demanding. Strict control over impurities, including stereoisomers and related substances, is essential.
• Limited Number of Qualified Suppliers: Historically, the number of manufacturers with the technical capability and regulatory approval for bortezomib API has been limited, potentially leading to supply chain vulnerabilities.
• Regulatory Scrutiny: Regulatory bodies maintain a high level of scrutiny on oncology drug manufacturing, requiring robust quality systems and compliance.
• Cost of Production: The complex multi-step synthesis and rigorous quality control contribute to a relatively high cost of goods for bortezomib API.
• Intellectual Property Hurdles: Navigating the remaining intellectual property landscape, even after primary patent expiry, requires careful legal and technical due diligence to avoid infringement.

Opportunities:

• Emerging Generic Market: As key patents expire globally, there is a growing opportunity for generic API manufacturers to enter the market, increasing supply and driving down costs for finished drug products.
• Strategic CMO Partnerships: Companies can leverage partnerships with specialized CMOs that have proven expertise in complex peptide and boronic acid synthesis. These partnerships can facilitate efficient scale-up and regulatory compliance.
• Process Innovation: Opportunities exist for developing novel, more efficient, and environmentally friendly synthetic routes for bortezomib API that can also circumvent existing process patents.
• Supply Chain Diversification: The increasing number of qualified generic API manufacturers can lead to opportunities for diversifying the supply chain, reducing reliance on single sources and enhancing supply chain resilience.
• Emerging Markets: Expansion into emerging markets, where generic drug penetration is high, presents growth opportunities for API suppliers.

What are the Key Considerations for Sourcing Bortezomib API?

When sourcing bortezomib API, pharmaceutical companies must undertake a comprehensive evaluation process.

Key considerations include:

• Manufacturer Qualification:
  • cGMP Compliance History: Audit the manufacturer's facilities and review their regulatory inspection history (FDA, EMA, etc.).
  • Technical Expertise: Assess their proven experience in complex peptide synthesis, boronic acid chemistry, and handling of cytotoxic compounds.
  • Quality Control Systems: Evaluate their analytical capabilities, impurity control strategies, and batch-to-batch consistency records.
  • Capacity and Scalability: Ensure the manufacturer can meet projected volume requirements and has a clear plan for scaling up production.
• Regulatory Documentation:
  • DMF Status: Review the manufacturer's DMF for completeness and acceptance by target regulatory agencies.
  • Certificates of Analysis (CoAs): Scrutinize CoAs for all released API batches.
  • Regulatory Support: Confirm the manufacturer's willingness and ability to provide necessary regulatory support for marketing authorization applications.
• Intellectual Property (IP) and Freedom to Operate (FTO):
  • Patent Landscape Analysis: Conduct a thorough review of the patent landscape to ensure the proposed source and manufacturing process do not infringe on existing IP.
  • Supplier IP Statement: Request a declaration from the supplier regarding their IP status and freedom to sell the API.
• Supply Chain Reliability and Security:
  • Supply Chain Mapping: Understand the manufacturer's raw material sourcing and key intermediate suppliers to assess supply chain risks.
  • Business Continuity Planning: Review the manufacturer's plans for handling disruptions (e.g., natural disasters, geopolitical events).
  • Auditable Quality Agreements: Establish clear, legally binding Quality Agreements detailing responsibilities for quality, testing, change control, and recalls.
• Cost and Commercial Terms:
  • Pricing Structure: Negotiate competitive pricing based on volume, contract duration, and payment terms.
  • Lead Times: Understand production lead times and delivery schedules.
  • Total Cost of Ownership: Consider not only the API price but also costs associated with quality, regulatory support, and potential supply chain disruptions.
• Analytical Methods:
  • Method Validation: Ensure the manufacturer's analytical methods for API testing are validated and acceptable to regulatory authorities.
  • Reference Standards: Verify the availability and quality of reference standards for API testing.

A robust due diligence process, combining technical, quality, regulatory, and commercial assessments, is essential for mitigating risks and ensuring a reliable supply of bortezomib API.

Key Takeaways

• Bortezomib API manufacturing requires specialized expertise in complex peptide and boronic acid chemistry under strict GMP conditions.
• The supply landscape is evolving, with originator influence diminishing as primary patents expire, enabling generic API production.
• Key considerations for sourcing include stringent cGMP compliance, robust impurity profiling, comprehensive stability data, and thorough intellectual property due diligence.
• Partnerships with qualified CMOs and generic API manufacturers are crucial for ensuring a reliable and cost-effective supply chain.

Frequently Asked Questions

1. Are there readily available lists of approved bortezomib API manufacturers? Publicly accessible, comprehensive lists are rare due to commercial confidentiality. Information is typically gathered through regulatory filings (DMFs), industry conferences, and direct supplier inquiries.
2. What is the typical lead time for securing a significant quantity of bortezomib API from a new supplier? Lead times can range from 6 to 18 months, depending on the supplier's existing capacity, the complexity of the technology transfer and validation required, and the scale of the order.
3. How does the presence of stereoisomers impact bortezomib API sourcing? Bortezomib has chiral centers, making stereochemical purity critical. Manufacturers must demonstrate control over the formation of specific stereoisomers and the removal of unwanted ones, requiring advanced analytical techniques.
4. Can a company source bortezomib API from a manufacturer not yet approved in their target market? While sourcing is possible, the API manufacturer must undergo the necessary regulatory inspections and file appropriate documentation (e.g., DMF) to gain approval in the target market before the finished drug product can be marketed there.
5. What are the main quality risks associated with bortezomib API synthesis? Major risks include incomplete reaction, formation of process-related impurities, degradation products, residual solvents, and achieving the correct stereochemical configuration, all of which can impact safety and efficacy.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from https://www.fda.gov/drugs/drug-master-files [2] European Medicines Agency. (n.d.). Good manufacturing practice. Retrieved from https://www.ema.europa.eu/en/human-regulatory/research-development/good-manufacturing-practice [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Harmonised Tripartite Guideline Quality - Impurities in New Drug Substances Q3A(R2). Retrieved from https://www.ich.org/page/quality-guidelines [4] U.S. Patent and Trademark Office. (n.d.). Patent Search. Retrieved from https://patft.uspto.gov/netahtml/PTO/search-general.html [5] United States Pharmacopeia. (n.d.). USP Drug Information. Retrieved from https://www.uspnf.com/